TRPV1 (vanilloid receptor, capsaicin receptor) agonists and antagonists

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 12, 2003, Pages 1825-1837

  Appendino, Giovanni ^a   Muñoz, Eduardo ^b   Fiebich, Bernd L ^c  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c VIVACELL BIOTECHNOLOGY GMBH   (Germany)

Author keywords

Analgesics; Capsaicin; Chronic pain; Transient receptor potential (TRP) channels; TRPV1; Vanilloid receptors

Indexed keywords

5 IODORESINFERATOXIN; ANANDAMIDE; ARVANIL; CANNABIDIOL; CAPSAICIN; CAPSAICIN DERIVATIVE; CAPSAVANIL; CAPSAZEPINE; CATION CHANNEL; DOXEPIN; EUGENOL; EVODIAMINE; GLYCERYL TRINITRATE; INDOMETACIN; ISOVELLERAL; KAVA; LIDOCAINE; MORPHINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; OLVANIL; PARACETAMOL; PROPANOCAINE; PROPOFOL; RESINIFERATOXIN; RETVANIL; RINVANIL; SB 366791; SDZ 249665; SESQUITERPENE LACTONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR;

ACIDITY; ALLODYNIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; BIOSENSOR; BLADDER DISEASE; CALCIUM DEPLETION; CHRONIC PAIN; CLINICAL TRIAL; COUGHING; DESENSITIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; EYE DISEASE; HEAT; HUMAN; LACRIMATION; MUSCLE DISEASE; NERVE CELL; NONHUMAN; OSMOLARITY; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SKIN IRRITATION; SPASTICITY; STRUCTURE ACTIVITY RELATION;

EID: 0346752069     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.12.1825     Document Type: Review

References (55)

1. MONTELL C, BIMBAUMER L, FLOCKERZI V: The TRP channels, a remarkably functional family. Cell (2002) 108:595-598.
2. GUNTHORPE MJ, BENHAM CD, RANDALL A, DAVIS JB: The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol. Sci. (2002) 23:183-191.
3. CATERINA MJ, SCHUMACHER MA, TOMINAGA M et al.: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 398:816-824.
4. MONTELL C, BIRNBAUMER L, FLOCKERZI V et al.: A unified nomenclature for the superfamily of TRP cation channels. Mol. Cell (2002) 9:229-231.
5. PEIER AM, REEVE AJ, ANDERSSON DA et al.: A heat-sensitive TRP channel expressed in keratinocytes. Science (2002) 296:2046-2049.
6. SMITH GD, GUNTHORPE MJ, KELSELL RE et al.: TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature (2002) 418:186-190.
7. XU H, RAMSEY IS, KOTECHA SA et al.: TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature (2002) 418:181-186.
8. STERNER O, SZALLASI A: Novel natural vanilloid receptor agonists: new therapeutic targets for drug development. Trends Pharmacol. Sci.(1999) 20:431-439.
9. DI MARZO V, BLUMBERG PM, SZALLASI A: Endovanilloid signaling in pain. Curr. Opin. Neurobiol. (2002) 12:372-379.
10. SZALLASI A: Vanilloid (capsaicin) receptors in health and disease. Am. J. Clin. Pathol. (2002) 118:110-121.
11. SZALLASI A, BLUMBERG PM: Vanilloid (capsaicin) receptors and mechanisms. Pharmacol. Rev. (1999) 51:159-211.
12. HUANG SM, BISOGNO T, TREVISANI M et al.: An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA (2002) 99:8400-8405.
13. CHU CJ, HUANG SM, DE PETROCELLIS L et al.: N-Oleolydopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J. Biol. Chem. (2003) 278:13633-13639.
14. 2 binding site as a determinant of capsaicin receptor sensitivity. Science (2003) 300:1284-1288.
15. SZALLASI A: Vanilloid receptor ligands. Hopes and realities for the future. Drugs Aging (2001) 18:561-573.
16. LASTRES-BECKER I, DE MIGUEL R, DE PETROCELLIS L et al.: Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. (2003) 84:1097-1109.
17. NUMAZAKI M, TOMINAGA T, KUMIKO T et al.: Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc. Natl. Acad. Sci USA (2003) 100:8002-8006.
18. SZALLASI A: After a decade of intravescical vanilloid therapy: still more questions than answers. Lancet Neurobiol. (2002) 1:167-172.
19. KARLSSON JA: The role of capsaicin-sensitive C-fiber afferent nerves in the cough reflex. Pulm. Pharmacol. (1996) 9:315-321.
20. REILLY CA, EHLHARDT WJ, JACKSON DA et al.: Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem. Res. Toxicol. (2003) 16:336-349.
21. WATANABE H, VRIENS J, PRENEN J et al.: Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature (2003) 424:438-441.
22. WATANABE H, DAVIS JB, DARREN S et al.: Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J. Biol. Chem. (2002) 277:13569-13577.
23. MCINTYRE P, MCLATCHIE LM, CHAMBERS A et al.: Pharmacological differences between the human and the rat vanilloid receptor 1 (VR1). Br. J. Pharmacol. (2001) 132:1084-1094.
24. JORDT SE, JULIUS D: Molecular basis for species-specific sensitivity to 'hot' chili pepper. Cell (2002) 108:421-430.
25. SAVIDGE J, DAVIS C, SHAH K et al.: Cloning and functional characterization of the guinea-pig vanilloid receptor 1. Neuropharmacology (2002) 43:450-456.
26. KOBAYASHI Y, NAKANO Y, KIZAKI M et al.: Capsaicin-like anti-obese activities of evodiamine from fruits Evodia rutaecarpa, a vanilloid receptor antagonist. Planta Med. (2001) 67:628-633.
27. BISOGNO T, HANUS L, DE PETROCELLIS L et al.: Molecular targets for cannabidiol and its synthetic analogues: effects on vanilloid VR1 receptors and on cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol (2001) 134:845-852.
28. YANG BH, PIAO ZG, KIM YB et al.: Activation of vanilloid receptor 1 (VR1) by eugenol. J. Dent. Res. (2003) 82:781-785.
29. TOT A, KEDEI N, SZABO T et al.: Thapsigargicin binds to and inhibits the cloned vanilloid receptor-1. Biochem. Biophysi. Res. Commum. (2002) 293:777-782.
30. IIDA T, MORIYAMA T, KOBATA K et al.: TRPV1 activation and induction of nociceptive response by a non-pungent capsaicin-like compound, capsiate. Neuropharmacology (2003) 44:958-967.
31. MACHO A, LUCENA C, SANCHO R et al.: Non-pungent capsacinoids from sweet pepper. Synthesis and evaluation of the chemopreventive and anticancer potential. Eur. J. Nutr. (2003) 42:2-9.
32. TSUTUMI S, TOMIOKA A. SUDO M et al.: Propofol activates vanilloid receptor channels expressed in human embryonic kidney-293 cells. Nerosci. Lett. (2001) 312:45-49.
33. APPENDINO G, MINASSI A, SCHIANO MORELLO A et al.: N-Acylvanillamides: development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor. J. Med. Chem. (2002) 45:3739-3745.
34. URBAN L, CAMPBELL EA, PANESAR M et al.: In vivo pharmacology of SDZ-249665, a novel, non-pungent capsaicin analogue. Pain (2000) 89:65-74.
35. ZYGMUNT PM, CHUANG H, MOVAHED P et al.: The anandamide transport inhibitor AM-404 activates vanilloid receptors. Eur. J. Pharmacol. (2000) 396:39-42.
36. GUHRING H, HAMZA M, SERGEJEVA M et al.: A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur. J. Pharmacol. (2002) 454:153-163.
37. MCVEY DC, SCHMID PC, SCHMID HHO et al.: Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J. Pharmacol. Exp. Ther. (2003) 304:713-722.
38. PARK NS, SEONG CM, JUNG YS et al.: DA-5018 (Capsavanil, KR-25018). Drugs Fut. (2000) 25:1131-1137.
39. SZOLCSANYI J, JANCSO-GABOR A: Sensory effects of capsaicin congeners. Artzneim. Forsch. (1975) 25:1877-1881.
40. SZALLASI A, BLUMBERG PM: Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analogue of capsaicin, the irritant constituent in red pepper. Neuroscience (1989) 30:515-520.
41. LEE J, PARK SU, KIM JY et al.: 3-Acyloxy-2-phenalkylpropyl amides and esters of homovanillic acid as novel vanilloid receptor agonists. Bioorg. Med. Chem. Lett. (1999) 9:2909-2914.
42. LEE J, LEE J, KANG MS et al.: Phenolic modification as an approach to improve the pharmacology of the 3-acyloxy-2-benzylpropyl homovanillic amides and thioureas, a promising class of vanilloid receptor agonists and analgesics. Bioorg. Med. Chem. (2002) 10:1171-1179.
43. LEE J, LEE J, KIM J et al.: N-(3-Acyloxy-2-benzylpropyl)-N′-(4-hydroxy-3-methoxybenzyl)thiourea derivatives as potent vanilloid receptor agonists and analgesics. Bioorg. Med. Chem. (2001) 9:19-22.
44. WALPOLE CSI, BEVAN S, BOVERMANN G et al.: The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J. Med. Chem. (1994) 37:1942-1954.
45. WAHL P, FOGED C, TULLIN S et al.: Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol. Pharmacol. (2001) 59:9-15.
46. MCDONNEL ME, ZHANG SP, DUBIN AE et al.: Synthesis and in vitro evaluation of a novel iodinated resiniferatoxin derivative that is an agonist at the human vanilloid VR1 receptor. Bioorg. Med. Chem. Lett. (2002) 12:1189-1192.
47. APPENDINO G, HARRISON S, DE PETROCELLIS L et al.: Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br. J. Pharmacol (2003) 139:1417-1424.
48. SEABROOK GR, SUTTON KG, JAROLIMEK W et al.: Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodoresiniferatoxin. J. Pharmacol. Exper. Therap. (2002) 303:1052-1060.
49. LEE J, LEE J, KANG M et al.: N-(Methylsulfonylamino)benzyl thiourea analogues: novel potent and high affinity antagonists of vanilloid receptors. J. Med. Chem. (2003) 46:3116-3126.
50. RAMI HK, DAVIDS JB, GUNTHORPE MJ et al.: Identification of SB-366791, a potent and selective antagonist of vanilloid receptor-1. Drugs Fut. (2002) 27(Suppl.A):411.
51. YOON JW, CHOI HY, LEE HJ et al.: Chain-branched acyclic phenethylthiocarbamates as vanilloid receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13:1549-1552.
52. LEE SH, PREMKUMAR LS: Inhibition of capsaicin-induced single channel currents by cocaine. Soc. Neurosci. Abstr. (1999) 25:2255.
53. HAHN JH: Ginsenosides inhibit capsaicin channels in rat dorsal root ganglion neurons. Neurosci. Lett. (2000) 287:45-48.
54. DAX S, DUBIN A, JETTER M et al.: Vanilloid receptor antagonists: structure-activity relationships via parallel and targeted synthesis. Drugs Fut. (2002) 27(Suppl.A):93.
55. WALKER KM, URBAN L, MEDHURST SJ et al.: The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J. Pharmacol Exp. Ther. (2003) 304:56-62.